Large-Scale Study Provides First-Ever Insights into the Genetic Causes of Bedwetting
New evidence from the world’s first genome-wide association study (GWAS) identifies genes and genetic variants associated with bedwetting and may lead to earlier identification of children predisposed to bedwetting and improved earlier treatment options.The results are being presented by the International Children’s Continence Society (ICCS) and the European Society for Paediatric Urology (ESPU) on World Bedwetting Day on 29 May 2018.
“We have known for over a century, there has been strong evidence suggesting a genetic background for bedwetting.2 The risk of bedwetting is 5-7 times higher among children with a parent who suffered from bedwetting as a child, and approximately 11 times higher if both parents were bedwetters”,1 said Dr. Søren Rittig, Professor at the Department of Child and Youth, Nephro-urologic Team, Aarhus University Hospital who together with associate professor Jane Hvarregaard Christensen, Department of Biomedicine, Aarhus University is responsible for this new study.
Bedwetting is a common medical condition that has a serious impact on a child’s self-esteem, emotional well-being and day time functioning, including school and social performance3,4,5; and improvements in their working memory and other daily activities have been seen after treatment.6
The GWAS used the iPSYCH2012 nationwide population-based sample of around 80,000 Danish individuals collected to study among others ADHD and autism. Genome-wide association studies work by scanning markers across the entire genome of large numbers of people in order to find genetic variants associated with a particular disease.
Associate professor Jane Hvarregaard Christensen said, “By comparing the frequency of millions of genetic variants in thousands of DNA samples from bedwetting children we have been able to demonstrate specific genetic variants that each contribute to increase the risk of bedwetting. The genes implicated by this are known to function in deep brain areas responsible for regulation of day-night rhythms, urine production and sleep. This supports that bedwetting is linked to physiological mechanisms rather than being caused by psychological problems.” This is an important first step to provide new insights into the biological processes leading to bedwetting.
There are at least two main reasons why children are bedwetting – a reduced bladder capacity and/or an increased urine production during night-time (polyuria). By analyzing millions of genetic variants in bedwetting children, researchers were able to point to specific genes and thereby suggest specific biological causes of bedwetting.
Dr. Søren Rittig said, “We believe further research using the genes and genetic variants we have detected could help us identify bedwetting children earlier, determine which children would benefit from medication and tailor treatment to alleviate their condition.”
Bedwetting, also known as nocturnal enuresis, is an uncontrollable leakage of urine while asleep.7 In most cases it is caused by over-production of urine at night or reduced capacity of the bladder.4 An inability to wake up can be another cause.4 Bedwetting does not seem to have a psychological cause.4 Bedwetting is a common childhood medical condition, with approximately 5–10% of 7-year-olds regularly wetting their beds and the problem may persist into teenage and adulthood.8
About World Bedwetting Day
World Bedwetting Day was initiated to raise awareness among the public and healthcare professionals that bedwetting is a common medical condition that can and should be treated.
World Bedwetting Day 2018 will take place on 29 May and occurs on the last Tuesday of May each year. The theme is: ‘Time to Take Action’, in recognition that much more can be done to diagnose and treat those children who suffer from bedwetting.
For more information please visit www.worldbedwettingday.com.
About the World Bedwetting Day Steering Committee
The World Bedwetting Day Steering Committee brings together experts from across the globe to support this initiative and consists of the International Children’s Continence Society (ICCS), the European Society of Paediatric Urology (ESPU), the Asia Pacific Association of Paediatric Urology (APAPU), the International Paediatric Nephrology Association (IPNA), the European Society of Paediatric Nephrology (ESPN), the Sociedad Iberoamericana de Urologia Paediatrica (SIUP), and the North American Paediatric Urology Societies. The initiative is supported by Ferring Pharmaceuticals.
1 Jarvelin, M. R., Vikevainen-Tervonen, L., Moilanen, I. &
Huttunen, N. P. Enuresis in seven-year-old children. Acta paediatrica
77, 148-153 (1988).
2 von Gontard, A., Schaumburg, H., Hollmann, E., Eiberg, H. & Rittig, S. The genetics of enuresis: a review. The Journal of urology 166, 2438-2443 (2001).
3 Iannelli V. Bedwetting. Available at https://www.verywell.com/bedwetting-bedwetting-statistics-2633257. Last accessed January 2017.
4 Vande Walle J et al, Practical consensus guidelines for the management of enuresis. Eur J Pediatr 2012;171:971-98
5 Joinson C et al. A United Kingdom population-based study of intellectual capacities in children with and without soiling, daytime wetting, and bed-wetting Pediatrics. 2007;120(2):e308-16
6 Van Herzeele C, Dhondt K, Roels S P et al. Desmopressin (melt) therapy in children with monosymptomatic nocturnal enuresis and nocturnal polyuria results in improved neuropsychological functioning and sleep. Pediatr Nephrol. 2016; DOI 10.1007/s00467-016-23351-3
7 Austin P et al. The Standardization of Terminology of Lower Urinary Tract Function in Children and Adolescents: Update Report from the Standardization Committee of the International Children’s Continence Society, The Journal of Urology. 2014;191:1863-1865
8 Nevéus T. Nocturnal enuresis—theoretic background and practical guidelines. Pediatr Nephrol. 2011; 26:1207–1214
Burson-Marsteller, on behalf of World Bedwetting Day Steering Committee
Jack Dixey, +44 (0)207 300 6221
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EEST | Tiedote
ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B
Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EEST | Tiedote
Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan
Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EEST | Tiedote
Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste
WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EEST | Tiedote
The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici
Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EEST | Tiedote
Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an
CNT Among SAP’s "Best of the Best"17.5.2019 11:00:00 EEST | Tiedote
Since 2005, SAP is honoring the best of the best SAP projects yearly in Europe, Middle East and Africa. In 2018, 280 customers from 15 markets submitted their regional Gold Award-winning projects. CNT Management Consulting from Vienna won Bronze twice – together with its customers HOERBIGER and TANNPAPIER – a happy day for CNT’s CEO Andreas Doerner. "We are now on the podium for the second time with two projects – thanks to the trust of our customers." The SAP Quality Awards EMEA were presented at an exceptionally festive ceremony in Heidelberg Castle (Baden-Wuerttemberg), and only twelve SAP customers were able to take home the most wanted trophies that were presented by SAP Presidents Brian Duffy (EMEA North) and Hartmut Thomsen (Middle and Eastern Europe). The jury evaluated the projects according to the ten SAP quality principles and the question of whether the respective project could fulfill the expectations of its clients. HOERBIGER - Category Business Transformation Headquarter
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme